ClinicalTrials.gg
CompletedNCT02394132RADICALUpdated Jun 20, 2024

Radiotherapy or Imiquimod in Complex Lentigo Maligna

A Phase 3 interventional study of Imiquimod and Radiotherapy in Lentigo Maligna, sponsored by Melanoma and Skin Cancer Trials Limited. Completed at 10 sites in 3 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by Melanoma and Skin Cancer Trials Limited · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the effectiveness of using either radiotherapy (RT) or Imiquimod (ImiQ) to treat the Lentigo Maligna (LM), when surgery is not possible, is refused, or fails.

Read the detailed description

Surgery is the standard treatment for people diagnosed with LM. However for some people, it may not be possible due to the location of their LM lesion(s).

Currently, the Australian and New Zealand Melanoma Treatment Guidelines recommend radiotherapy for the treatment of LM however there is no clinical trial evidence for this and a trial is needed to prove which treatment is safer and more effective. Some clinicians may also recommend the use of a cream called Imiquimod. It is approved and widely used in Australia to treat solar keratosis, superficial basal cell carcinoma, external genital warts, and perianal warts. Although not currently licensed for treatment use in LM, there is some evidence to suggest that it is both safe and effective in treating LM.

This trial will scientifically evaluate and compare these two treatments in a controlled clinical setting.

The primary objective of this trial is to compare the rate of LM treatment failure and recurrence rate measured at 24 months (primary endpoint), and measured at 6, 12 months (secondary endpoints) following treatment with ImiQ or RT. For this study, treatment failure includes both the recurrence and persistence of LM, and is defined as the presence of LM cells within the original field of treatment confirmed by histopathology.

02

Conditions studied

  • Lentigo Maligna

Keywords

  • Lentigo maligna
  • Imiquimod
  • Radiotherapy
03

In context

Lead sponsor

Melanoma and Skin Cancer Trials Limited is the lead sponsor of 15 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or older.
  2. A -proven LM. This includes previous treatment failures (not with imiquimod or RT) of LM that are diagnosed as biopsy-proven LM.
  3. LM that is in a location amenable to treatment with imiquimod and radiotherapy.
  4. Willing and able to comply with study requirements.
  5. Written .

Exclusion criteria

Exclusion Criteria:

  1. Invasive melanoma.
  2. Medical or psychiatric condition that compromises the ability of the patient to complete protocol treatment or follow-up assessments.
  3. Patients who are pregnant or lactating. Women of child bearing potential must have a confirmed negative urine pregnancy test at study entry.
  4. of less than 2 years.
  5. Radiotherapy sensitivity syndrome
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Imiquimod

    Topical imiquimod 5% cream * application to treatment area for 5 days/week for a total of 12 weeks * dispensed at baseline visit along with patient diary

    Drug: Imiquimod

  • Experimental
    Radiotherapy

    Radiotherapy * treatment regimen determined by treating radiation oncologist and as per standard practice at local institution * treatment to commence within 8 weeks of randomisation

    Radiation: Radiotherapy

Interventions

  • Also known as: Aldara

  • RadiationRadiotherapy
06

What researchers measure

Primary outcomes

  1. Proportion of patients experiencing LM treatment failure

    Determined by systematic biopsy, 6 months following completion of treatment.

    Time frame: 6 months

Secondary outcomes

  1. LM treatment failure at 12 months and 24 months after the completion of treatment.

    Determined by dermoscopy and/or Reflectance Confocal Microscopy and confirmed by biopsy

    Time frame: 12 and 24 months

  2. Quality of life using Skindex-16 questionnaire

    Patient Reported outcomes were collected using the dermatology specific quality of life instrument Skindex-16 with additional questions specifically selected from the Skindex-29. The Skindex-16 instrument covers three domains: Symptoms, 4 items; Function, 5 items; Emotions, 7 items. Standard scoring of domain scores uses the average of the component items, transformed to 0-100 scale, with higher scores indicating a greater negative impact of skin disease on quality of life (function, emotions) and greater symptom experience.

    Time frame: 0-24 months

  3. Quality of life using Skindex-29 questionnaire

    Due to the nature of this study it was decided to include additional questions from the Skindex-29 instrument (Q2, Q9 and Q18) as these questions address potential issues not covered by the Skindex-16.Similar to the Skindex-16, all responses are transformed to a linear scale of 100, with higher scores indicating more negative impact.

    Time frame: 0-24 months

  4. Cosmetic outcome 24 months after treatment or at treatment failure

    Evaluated using photographs taken of LM lesion(s) during the study

    Time frame: 24 months

  5. Incidence of invasive melanoma within treatment fields; a sub-study to evaluate the utility of reflectance confocal microscopy (RCM) compared with standard biopsy in diagnosing recurrence

    Assessed at all time-points (6, 12 and 24 months post treatment). Time to failure of LM treatment and diagnosis with invasive melanoma within the treatment field was compared for each treatment arm using the log-rank test and Kaplan-Meier curves.

    Time frame: 0-24 months

07

Study locations

10 sites
  • Calvary Mater Newcastle
    Newcastle, New South Wales 2298, Australia
  • Melanoma Institute Australia
    North Sydney, New South Wales 2060, Australia
  • Skin and Cancer Foundation
    Sydney, New South Wales 2010, Australia
  • Westmead Hospital
    Sydney, New South Wales 2145, Australia
  • St Vincent's Hospital, Sydney
    Sydney, New South Wales, Australia
  • Princess Alexandra Hospital
    Brisbane, Queensland 4102, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Hospital das Clinicas, University of Sao Paulo
    São Paulo, Brazil
  • North Shore Hospital
    Takapuna, Auckland 0740, New Zealand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Dec 2021, 75 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2015
First posted
Mar 20, 2015
StartActual
Aug 31, 2015
Primary completionActual
Dec 24, 2021
CompletionActual
Mar 30, 2023
Last update
Jun 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02394132
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Collaborators
Melanoma Institute Australia
Responsible party
Sponsor
First posted
Mar 20, 2015
Start date
Aug 31, 2015
Primary completion
Dec 24, 2021
Completion
Mar 30, 2023
Last update
Jun 20, 2024

Study contacts

Pascale Guitera
principal investigator · Melanoma Institute Australia

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imiquimod

Start the discussion